DSpace Collection:https://hdl.handle.net/10171/190252024-03-28T20:43:44Z2024-03-28T20:43:44ZRevisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancerhttps://hdl.handle.net/10171/689062024-02-12T06:08:05Z2023-01-01T00:00:00ZTitle: Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer
Abstract: Prostate cancer (PCa) is a disease that exhibits het-
erogeneity in terms of its clinical behavior [1]. There-
fore, it is not surprising that heterogeneity also affects
the way we treat PCa.
Radical treatments such as radical prostatectomy (RP)
and radiation therapy (RT) have for years been consid-
ered the standard of care for most men with non-meta-
static PCa [2,3]. During the last 120 years, many changes
regarding surgical and radiation techniques have arose
to reduce morbidity and improve oncological and func-
tional outcomes [4]. However, despite all of the effort
behind these advances, the negative effects on sexual,
urinary and bowel function remain unsolved [5].2023-01-01T00:00:00ZRecipient and donor risk factors for surgical complications following kidney transplantationhttps://hdl.handle.net/10171/689032024-02-12T06:08:03Z2012-01-01T00:00:00ZTitle: Recipient and donor risk factors for surgical complications following kidney transplantation
Abstract: Objective. The aim of this study was to evaluate recipient and donor risk factors that are related to surgical complications after renal transplantation. Material and methods. In total, 419 kidney transplantations were analysed with regard to the influence of recipient and donor risk factors on the main postoperative surgical complications. Results. The mean follow-up for the entire group was 72.8 months (± 54.2 SD). Vascular complications were independently associated with donor age; and urological complications with recipient age >65 years and cyclosporine rather than tacrolimus therapy. Wound complications were independently associated with recipient age, preoperative dialysis time, recipient body mass index (BMI) and cyclosporine rather than tacrolimus therapy. Collections were independently associated with retransplantation, type 2 diabetes mellitus and wound complications. Overall surgical complications were associated with donor age and delayed graft function. In terms of severity, grade I complications were independently associated with recipient age and surgical revision, grade II with recipient age >50 years, grade III with recipient BMI, and grade IV with donor age. Conclusions. Recipient characteristics are the primary determinants of wound, urological and minor (Clavien grades I, II and III) complications; however, graft or donor characteristics are the primary risk factors for vascular, overall and major (Clavien grade IV) surgical complications.2012-01-01T00:00:00ZIdentification of mutations associated with acquired resistance to sunitinib in renal cell cancerhttps://hdl.handle.net/10171/689022024-02-12T06:08:02Z2019-01-01T00:00:00ZTitle: Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
Abstract: Sunitinib is one of the most widely used targeted therapeutics for renal cell carcinoma (RCC), but acquired resistance against
targeted therapies remains a major clinical challenge. To dissect mechanisms of acquired resistance and unravel reliable
predictive biomarkers for sunitinib in RCC, we sequenced the exons of 409 tumor-suppressor genes and oncogenes in paired
tumor samples from an RCC patient, obtained at baseline and after development of acquired resistance to sunitinib. From
newly arising mutations, we selected, using in silico prediction models, six predicted to be deleterious, located in G6PD,
LRP1B, SETD2, TET2, SYNE1, and DCC. Consistently, immunoblotting analysis of lysates derived from sunitinib-desensitized
RCC cells and their parental counterparts showed marked differences in the levels and expression pattern of the proteins
encoded by these genes. Our further analysis demonstrates essential roles for these proteins in mediating sunitinib
cytotoxicity and shows that their loss of function renders tumor cells resistant to sunitinib in vitro and in vivo. Finally, sunitinib
resistance induced by continuous exposure or by inhibition of the six proteins was overcome by treatment with cabozantinib or
a low-dose combination of lenvatinib and everolimus. Collectively, our results unravel novel markers of acquired resistance to
sunitinib and clinically relevant approaches for overcoming this resistance in RCC.2019-01-01T00:00:00ZNew Immunosuppressive Therapies and Surgical Complications After Renal Transplantationhttps://hdl.handle.net/10171/689002024-02-12T06:08:03Z2012-01-01T00:00:00ZTitle: New Immunosuppressive Therapies and Surgical Complications After Renal Transplantation
Abstract: Background:
To analyze the association between the principal immunosuppressive drugs (mycophenolate mofetil, calcineurin inhibitors and mammalian target of rapamycin [mTOR] inhibitors) used in the routine management of kidney transplant patients and the development of postoperative surgical complications.
Materials and Methods:
We analyzed 415 kidney transplants, studying the influence of various immunosuppressive regimens on the main postoperative surgical complications.
Results:
The mean follow-up for the entire group was 72.8 months (± 54.2 SD). Patients treated with myeophonolate mofetil (MMF) and cyclosporine (n = 121) experienced a higher frequency of wound eventration odds ratio [OR], 5.2; 95% confidence interval [CI], 1.2–23.5; P = .03) compared with azathioprine and cyclosporine (n = 71). Compared with transplant recipients treated with tacrolimus and MMF (n = 181), transplant recipients treated with cyclosporine and MMF (n = 121) had a significantly greater frequency of wound eventration (OR, 3.7; 95% CI, 1.5–9.5; P = .005), urologic (OR, 2; 95% CI; 1.02–3.9; P = .04), wound (OR; 2.2; 95% CI; 1.07–4.6; P = .03), late (OR, 1.7; 95% CI; 1.01–3.03; P = .04), and Clavien grade 3 surgical complications (OR; 1.9; 95% CI, 1.1–3.37; P = .01). Patients treated with mTOR inhibitors (n = 26) had higher rates of lymphocele (OR, 3.6; 95% CI, (1.1–11.4; P = .002) compared with those who received tacrolimus (n = 197).
Conclusions:
New immunosuppressive drugs have improved short-term functional results; however, in some cases they seem to increase surgical complications rates.2012-01-01T00:00:00Z